||A lymphoma that grows quickly and is currently curable in about 30-40% of patients with
standard CHOP chemotherapy.
||A type of protein made by certain white blood cells in response to a foreign substance
(antigen). Each antibody can bind to only a specific antigen. The purpose of this
binding is to help destroy the antigen. Antibodies can work in several ways, depending
on the nature of the antigen. Some antibodies destroy antigens directly. Others make it
easier for white blood cells to destroy the antigen.
||Treatment with an antibody, a substance that can directly kill specific tumor cells or
stimulate the immune system to kill tumor cells.
||Substances that cause the immune system to make a specific immune response. An example
would be a murine antibody, which is derived solely from mouse proteins and therefore is
viewed as foreign by the host body.
||White blood cells that make antibodies and are an important part of the immune system.
||The soft, sponge-like tissue in the center of bones that produces white blood cells, red
blood cells, and platelets.
|bone marrow toxicity
||The destruction of bone marrow using radiation or drugs.
||Refers to the fact that the antibody is made of both mouse and human antibodies, usually
a 30/70 percent split, respectively.
||Treatment using more than one anticancer drug.
||The disappearance of all detectable signs of cancer. Also called a complete response.
||The disappearance of all detectable signs of cancer in response to treatment. This does
not mean the cancer has been cured.
||A treatment that is given at the same time as another.
||Chemotherapy treatments given after induction chemotherapy to further reduce the number
of cancer cells.
||Cancer that continues to grow or spread.
||Length of time after treatment during which no cancer is found. Can be reported for an
individual patient or for a study population.
|duration of response
||Refers to the length of time between anticancer treatments where a patient's cancer
shrinks, disappears, or remains stable.
||Ongoing survival following cancer treatment without any events including disease
progression, relapse, death or initiation of new treatment.
||The antibody contains over 90 percent human material.
||The activity of the immune system against foreign substances (antigens). This type of
response can occur when a mouse or murine antibody is administered.
||A lymphoma that is slow growing and has few symptoms. It is incurable with current
||Treatment designed to be used as a first step toward shrinking the cancer and in
evaluating response to drugs and other agents. Induction therapy is followed by
additional therapy to eliminate whatever cancer remains.
||Side effects that are caused by toxic substances or something harmful to the body and do
not go away.
||Treatment that is given to help a primary (original) treatment keep working. Maintenance
therapy is often given to help keep cancer in remission or prolong a response to a
|murine (mouse) antibody
||The antibody is derived solely from mouse proteins and is viewed as foreign by the host
||The percentage of subjects in a study who have survived for a defined period of time.
Usually reported as time since diagnosis or initial treatment. Often called the survival
||A decrease in the size of a tumor, or in the extent of cancer in the body has regressed
by more than 50 percent in response to anticancer treatment.
||Treatment with a radioactive substance that is linked to an antibody, usually a mouse
||An unstable element that releases radiation as it breaks down. Radioisotopes can be used
in imaging tests or as a treatment for cancer.
||Any compound that has been joined with a radioactive substance.
||The treatment of disease (especially cancer) by exposure to a radioactive substance.
||The return of cancer, at the same site as the original (primary) tumor or in another
location, after the tumor had disappeared.
||The return of signs and symptoms of cancer after a period of improvement.
||The percentage of patients whose cancer shrinks more than 50 percent or disappears after
||Refers to the ability for a patient to receive the same therapy more than once for
||Treatment that is given after the cancer has not responded to other treatments.
||A currently accepted and widely used treatment for a certain type of cancer, based on
the results of past research.